Technically old news, but new article.
Sort of hard to reconcile the dichotomy of SGMO at $8.10 against the backdrop of SGMO performed pre clinical work that helps to validate this white hot burgeoning space in CAR-TRegs for autoimmune diseases that is seeing new companies enter the space seemingly daily, some with private seed money that likely gives them valuations on par with SGMO presently when they have nothing else going on.
It either speaks to the tremendous value that SGMO is, or the tremendous value trap that SGMO is...
It's almost as if it has already been assumed that even though SGMO was first here too, it will ultimately get leapfrogged yet again.
I have harped incessantly on execution, and with respect to CAR-TRegs, it is paramount here more than ever.